CO6300942A2 - Piridinas y pirazinas como inhibidores de p13k - Google Patents
Piridinas y pirazinas como inhibidores de p13kInfo
- Publication number
- CO6300942A2 CO6300942A2 CO10129427A CO10129427A CO6300942A2 CO 6300942 A2 CO6300942 A2 CO 6300942A2 CO 10129427 A CO10129427 A CO 10129427A CO 10129427 A CO10129427 A CO 10129427A CO 6300942 A2 CO6300942 A2 CO 6300942A2
- Authority
- CO
- Colombia
- Prior art keywords
- pirazinas
- piridines
- inhibitors
- salt
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
La presente invención se refiere a un compuesto de la fórmula (I)o una sal, de una manera adecuada una sal farmacéuticamente aceptable, o un solvato del mismo, en donde los grupos R1, R2, Ar , A e Y se definen en la descripción, a composiciones y al uso de los compuestos en el tratamiento de condiciones inflamatorias y alérgicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08153045 | 2008-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6300942A2 true CO6300942A2 (es) | 2011-07-21 |
Family
ID=39512639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10129427A CO6300942A2 (es) | 2008-03-19 | 2010-10-19 | Piridinas y pirazinas como inhibidores de p13k |
Country Status (23)
Country | Link |
---|---|
US (2) | US8268834B2 (es) |
EP (2) | EP2257529B1 (es) |
JP (1) | JP2011515362A (es) |
KR (1) | KR101284517B1 (es) |
CN (1) | CN102036961B (es) |
AR (1) | AR070923A1 (es) |
AU (1) | AU2009226958B2 (es) |
BR (1) | BRPI0909417A2 (es) |
CA (1) | CA2718526A1 (es) |
CL (1) | CL2009000650A1 (es) |
CO (1) | CO6300942A2 (es) |
CR (1) | CR11683A (es) |
EA (1) | EA018065B1 (es) |
EC (1) | ECSP10010556A (es) |
ES (1) | ES2455721T3 (es) |
IL (1) | IL208107A0 (es) |
MA (1) | MA32231B1 (es) |
MX (1) | MX2010010155A (es) |
NZ (1) | NZ587926A (es) |
PE (1) | PE20091687A1 (es) |
TW (1) | TW200948800A (es) |
WO (1) | WO2009115517A2 (es) |
ZA (1) | ZA201006506B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263585B2 (en) * | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
AR070924A1 (es) | 2008-03-19 | 2010-05-12 | Novartis Ag | Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona |
JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
PT3354650T (pt) | 2008-12-19 | 2022-06-20 | Vertex Pharma | Compostos úteis como inibidores da cinase atr |
WO2010108074A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
BR112012011465A2 (pt) * | 2009-10-30 | 2020-08-25 | Janssen Pharmaceutica N .V. | pirazinas como moduladores do receptor delta opioide. |
MY173795A (en) | 2009-11-05 | 2020-02-24 | Incozen Therapeutics Pvt Ltd | Novel benzopyran kinase modulators |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
EP2569286B1 (en) * | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
CN102718745A (zh) * | 2011-03-30 | 2012-10-10 | 中国科学院上海药物研究所 | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
MY168757A (en) | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
CA2850566C (en) | 2011-09-30 | 2022-05-03 | Vertex Pharmaceuticals Incorporated | Process for making 4-[chloro-n-hydroxycarbonimidoyl]phenyl derivative |
IN2014CN02501A (es) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
KR102083041B1 (ko) | 2012-02-22 | 2020-05-27 | 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 | 술폰아미드 화합물 및 tnap 억제제로서 용도 |
JP2015515478A (ja) | 2012-04-05 | 2015-05-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法 |
RU2638540C1 (ru) | 2012-04-24 | 2017-12-14 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
SI3260455T1 (sl) | 2012-07-04 | 2019-07-31 | Rhizen Pharmaceuticals S.A. | Selektivni inhibitorji PI3K-delta |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
HRP20211855T1 (hr) | 2013-03-12 | 2022-03-04 | Vertex Pharmaceuticals Incorporated | Inhibitori dnk-pk |
CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
KR102376354B1 (ko) * | 2013-03-29 | 2022-04-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 phd의 저해제로서의 그의 용도 |
PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EP3094326A4 (en) | 2014-01-14 | 2017-07-26 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
DK3102208T3 (da) * | 2014-02-07 | 2021-03-08 | Global Blood Therapeutics Inc | Krystallinsk polymorf af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd |
CN103804312B (zh) * | 2014-02-17 | 2016-04-20 | 四川百利药业有限责任公司 | 一类氮杂环化合物及其制备方法和用途 |
BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
CA2945257A1 (en) * | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
EA032075B1 (ru) | 2014-04-24 | 2019-04-30 | Новартис Аг | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
GB201715410D0 (en) * | 2017-09-22 | 2017-11-08 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
US11306079B2 (en) | 2017-12-21 | 2022-04-19 | Incyte Corporation | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors |
CN112088157B (zh) * | 2017-12-22 | 2023-12-26 | 拉文纳制药公司 | 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物 |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
KR20220100544A (ko) | 2021-01-08 | 2022-07-15 | 고려대학교 산학협력단 | PI3K/Akt 매개 후기 나트륨 전류 억제를 통한 부정맥 치료용 약학 조성물 및 치료방법 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30583A (en) * | 1860-11-06 | Milkibtg-stool | ||
GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
BE757702A (fr) | 1969-10-20 | 1971-04-19 | Sandoz Sa | Derives de la pyrido (2,3-d) pyrimidine, leur preparation et medicaments les contenant. |
US4297360A (en) * | 1980-03-28 | 1981-10-27 | Sterling Drug Inc. | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use |
GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
US5451700A (en) | 1991-06-11 | 1995-09-19 | Ciba-Geigy Corporation | Amidino compounds, their manufacture and methods of treatment |
WO1997043267A1 (en) | 1996-05-11 | 1997-11-20 | Kings College London | Pyrazines |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
PL203116B1 (pl) | 1999-05-04 | 2009-08-31 | Schering Corp | Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
CN1524527A (zh) | 1999-05-04 | 2004-09-01 | ���鹫˾ | 用作ccr5拮抗剂的哌啶衍生物 |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
EP1295121B1 (en) | 1999-12-22 | 2006-03-08 | PerkinElmer BioSignal Inc. | A bioluminescence resonance energy transfer (bret) system with broad spectral resolution between donor and acceptor emission wavelengths and its use |
KR100751981B1 (ko) | 2000-06-27 | 2007-08-28 | 라보라토리오스 살바트, 에스.에이. | 아릴알킬아민으로부터 유도된 카바메이트 |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
EP1305329B2 (en) | 2000-08-05 | 2015-03-18 | Glaxo Group Limited | 6.alpha.,9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyl)oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent |
PT1337527E (pt) | 2000-11-07 | 2009-12-10 | Novartis Ag | Derivados de indolilmaleimida como inibidores da proteína quinase c |
CA2441896A1 (en) | 2000-12-22 | 2002-07-04 | Almirall Prodesfarma Ag | Quinuclidine carbamate derivatives and their use as m3 antagonists |
CN1250545C (zh) | 2000-12-28 | 2006-04-12 | 阿尔米雷尔普罗迪斯制药有限公司 | 新的奎宁环衍生物类及含有这类衍生物的药物组合物 |
BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
US20040248867A1 (en) | 2001-06-12 | 2004-12-09 | Keith Biggadike | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
EP1578910A4 (en) | 2001-06-21 | 2008-06-04 | Verenium Corp | NITRILASES |
CZ2004501A3 (cs) | 2001-10-17 | 2004-09-15 | Ucb, S.A. | Chinuklidinové deriváty, způsoby jejich přípravy a jejich použití jako M2 a/nebo M3 inhibitoru muskarinového receptoru |
AR037517A1 (es) | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
IL162596A0 (en) | 2001-12-20 | 2005-11-20 | S A L V A T Lab Sa | 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists |
AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
EP1501514B1 (en) * | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
KR20050084224A (ko) | 2002-12-09 | 2005-08-26 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 야누스 티로신 키나제 3을 선택적으로 저해하는 방법 |
ES2401330T3 (es) * | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
EP1644365A2 (en) | 2003-07-02 | 2006-04-12 | Biofocus Discovery Ltd | Pyrazine and pyridine derivatives as rho kinase inhibitors |
EP1704145B1 (en) | 2004-01-12 | 2012-06-13 | YM BioSciences Australia Pty Ltd | Selective kinase inhibitors |
DE102004017934A1 (de) * | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
BRPI0513916A (pt) | 2004-07-27 | 2008-05-20 | Sgx Pharmaceuticals Inc | moduladores de pirrol-piridina cinase |
WO2006021886A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
DK1784396T3 (da) | 2004-08-26 | 2011-02-14 | Pfizer | Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
ZA200702435B (en) | 2004-10-12 | 2008-06-25 | Serono Lab | PI3 Kinase gamma inhibitors for the treatment of anaemia |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
PE20070978A1 (es) | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
US20090222270A2 (en) | 2006-02-14 | 2009-09-03 | Ivc Inc. | Voice command interface device |
RU2009106722A (ru) | 2006-07-28 | 2010-09-10 | Новартис АГ (CH) | 2,4-замещенные хиназолины в качестве ингибиторов липидной киназы |
KR100932093B1 (ko) | 2006-09-27 | 2009-12-16 | 주식회사종근당 | 미세소관 형성 저해제로서 유용한 벤조페논 유도체 |
GB0621607D0 (en) | 2006-10-31 | 2006-12-06 | Chroma Therapeutics Ltd | Inhibitors of c-Met |
JP2010518014A (ja) | 2007-01-31 | 2010-05-27 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用な2−アミノピリジン誘導体 |
US8263585B2 (en) * | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
AU2008278966B2 (en) * | 2007-07-26 | 2012-02-23 | Novartis Ag | Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions |
US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
CN102015686B (zh) * | 2008-03-21 | 2014-07-02 | 诺华股份有限公司 | 杂环化合物及其用途 |
-
2009
- 2009-03-04 US US12/380,901 patent/US8268834B2/en active Active
- 2009-03-17 JP JP2011500194A patent/JP2011515362A/ja active Pending
- 2009-03-17 AR ARP090100956A patent/AR070923A1/es not_active Application Discontinuation
- 2009-03-17 CN CN200980117994.2A patent/CN102036961B/zh not_active Expired - Fee Related
- 2009-03-17 BR BRPI0909417A patent/BRPI0909417A2/pt not_active IP Right Cessation
- 2009-03-17 EP EP09723200.3A patent/EP2257529B1/en active Active
- 2009-03-17 EA EA201001455A patent/EA018065B1/ru not_active IP Right Cessation
- 2009-03-17 AU AU2009226958A patent/AU2009226958B2/en not_active Ceased
- 2009-03-17 EP EP13153246.7A patent/EP2597085A1/en not_active Withdrawn
- 2009-03-17 MX MX2010010155A patent/MX2010010155A/es active IP Right Grant
- 2009-03-17 WO PCT/EP2009/053136 patent/WO2009115517A2/en active Application Filing
- 2009-03-17 CA CA2718526A patent/CA2718526A1/en not_active Abandoned
- 2009-03-17 KR KR1020107023197A patent/KR101284517B1/ko not_active IP Right Cessation
- 2009-03-17 ES ES09723200.3T patent/ES2455721T3/es active Active
- 2009-03-17 NZ NZ587926A patent/NZ587926A/xx not_active IP Right Cessation
- 2009-03-18 TW TW098108819A patent/TW200948800A/zh unknown
- 2009-03-18 CL CL2009000650A patent/CL2009000650A1/es unknown
- 2009-03-18 PE PE2009000404A patent/PE20091687A1/es not_active Application Discontinuation
-
2010
- 2010-09-10 ZA ZA2010/06506A patent/ZA201006506B/en unknown
- 2010-09-13 IL IL208107A patent/IL208107A0/en unknown
- 2010-09-21 CR CR11683A patent/CR11683A/es not_active Application Discontinuation
- 2010-10-15 MA MA33251A patent/MA32231B1/fr unknown
- 2010-10-19 EC EC2010010556A patent/ECSP10010556A/es unknown
- 2010-10-19 CO CO10129427A patent/CO6300942A2/es not_active Application Discontinuation
-
2012
- 2012-04-30 US US13/460,504 patent/US8846687B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2718526A1 (en) | 2009-09-24 |
NZ587926A (en) | 2012-08-31 |
AU2009226958A1 (en) | 2009-09-24 |
US8268834B2 (en) | 2012-09-18 |
CL2009000650A1 (es) | 2010-03-26 |
IL208107A0 (en) | 2010-12-30 |
ES2455721T3 (es) | 2014-04-16 |
WO2009115517A3 (en) | 2010-01-07 |
KR20100133439A (ko) | 2010-12-21 |
EP2257529A2 (en) | 2010-12-08 |
CR11683A (es) | 2010-10-29 |
BRPI0909417A2 (pt) | 2015-12-08 |
ZA201006506B (en) | 2011-06-29 |
KR101284517B1 (ko) | 2013-07-23 |
AR070923A1 (es) | 2010-05-12 |
CN102036961B (zh) | 2014-02-26 |
MX2010010155A (es) | 2010-11-04 |
US20120214800A1 (en) | 2012-08-23 |
EP2257529B1 (en) | 2014-01-01 |
EA018065B1 (ru) | 2013-05-30 |
WO2009115517A2 (en) | 2009-09-24 |
JP2011515362A (ja) | 2011-05-19 |
ECSP10010556A (es) | 2010-11-30 |
EP2597085A1 (en) | 2013-05-29 |
US20090239847A1 (en) | 2009-09-24 |
US8846687B2 (en) | 2014-09-30 |
EA201001455A1 (ru) | 2011-06-30 |
AU2009226958B2 (en) | 2012-06-14 |
CN102036961A (zh) | 2011-04-27 |
TW200948800A (en) | 2009-12-01 |
MA32231B1 (fr) | 2011-04-01 |
PE20091687A1 (es) | 2009-11-27 |
AU2009226958A8 (en) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6300942A2 (es) | Piridinas y pirazinas como inhibidores de p13k | |
SV2011003853A (es) | Compuestos organicos | |
CO6620055A2 (es) | Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos | |
CO6630154A2 (es) | Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
UY32490A (es) | Inhibidores de beta-secretasa | |
CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
NI201100048A (es) | Aminotriazolopiridinas y su uso como inhibidores de la cinasa. | |
ECSP14004812A (es) | Triazolopiridinas sustituidas | |
CO6361922A2 (es) | Inhibidores del virus de la hepatitis c | |
SV2010003464A (es) | Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas | |
PE20120495A1 (es) | 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas | |
CO6321276A2 (es) | Derivados de tiazol usados como inhibidores de pi3- cinasa | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
ECSP13013011A (es) | Triazolopiridinas | |
ECSP12012338A (es) | Triazolopiridinas sustituidas | |
CR20110264A (es) | Pirazolilaminopiridinas como inhibidores de fak | |
CR20110093A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
DOP2009000214A (es) | Macrolidos basados en eritromicina | |
CU20100179A7 (es) | Piridinas y pirazinas como inhibidores de p13k | |
CU20100014A7 (es) | Derivados de pirimidina útiles para el tratamiento de enfermedades inflamatorias o alérgicas | |
CU24174B1 (es) | Triazolopiridinas como inhibidores de quinasa mps-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted | ||
FD | Application lapsed |